CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 64 enrolled
Drug / intervention
Placebo to BI 691751 +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02057835
NCT02057835Phase 1Completed
CompareCT.gov

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers in a Randomised, Double-blind, Placebo-controlled Design.

Boehringer Ingelheim·interventional·Posted Feb 7, 2014·Updated Dec 16, 2015

In Brief

A Phase 1 clinical trial evaluating Placebo to BI 691751, BI 691751 high dose, and 3 other interventions for Healthy. Completed, enrolled 64 participants across 1 site.

Detailed Summary

BI 691751 is currently being developed to inhibit growth and prevent rupture of atherosclerotic plaques and to consequently reduce the risk of major cardiovascular events in patients with established atherosclerotic disease. 1334.5 is a Pan Asian Phase 1 study to investigate safety, tolerability and pharmacokinetics of BI 691751 in healthy Chinese and Japanese male volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSouth Korea
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 7, 2014
Enrollment StartMar 1, 2014
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.4 years ago

Interventions

Placebo to BI 691751drug

Placebo to BI 691751

BI 691751 high dosedrug

BI 691751 high dose

BI 691751 middle dosedrug

BI 691751 middle dose

Placebo to BI 691751drug

Placebo to BI 691751

BI 691751 low dose 1drug

BI 691751 low dose 1

Placebo to BI 691751drug

Placebo to BI 691751

Placebo to BI 691751drug

Placebo to BI 691751

BI 691751 low dose 2drug

BI 691751 low dose 2